Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases

Arase, Yoshitaka; Tsuruya, Kota; Hirose, Shunji; Ogiwara, Naoki; Yokota, Masashi; Anzai, Kazuya; Deguchi, Ryuzo; Shiraishi, Koichi; Shirai, Takayuki; Kagawa, Tatehiro

doi:10.1002/hep.30904

Public

Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases

Published in Hepatology • Aug 20, 2019

Authors:

Yoshitaka Arase

Kota Tsuruya

Shunji Hirose

Abstract

Potential conflict of interest: Nothing to report. Osteoporosis is a major complication in patients with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). Denosumab, a fully human monoclonal antibody against the receptor activator of nuclear factor‐dB ligand (RANKL), increases bone m...

Subject

Medicine

Denosumab

Autoimmune hepatitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!